trial

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

NCTId NCT03160521
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 438 (actual)
Sponsored by Rovi Pharmaceuticals Laboratories
Primary completion 2018-12-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
438 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2017-06-02
Primary completion
2018-12-17
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Rovi Pharmaceuticals LaboratoriesLead Sponsor

Investigators

2
Robert Litman, MDPrincipal Investigator
Yuriy FiltsPrincipal Investigator

Sites

31 total
Rogers, United StatesCerritos, United StatesGarden Grove, United StatesLemon Grove, United StatesLong Beach, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesHialeah, United StatesHollywood, United StatesAtlanta, United StatesGaithersburg, United States

Linked catalysts

1
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle ( — primary completion2018-12-17

Facts & assertions

4 sourced
Enrollment
438
Phase
PHASE3
Primary Completion Date
2018-12-17
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Rovi Pharmaceuticals Laboratories
company
indication
Acute Schizophrenia
indication
investigator
Robert Litman, MD
person
Yuriy Filts
person